IL17A and psoriasis: Although IL-17 plays a crucial role in neutrophil recruitment and activation, the frequency of neutropenia induced by Secukinumab in psoriasis, PsA, and AS is low, at 0.3, 0.2, and 0.5/100 person-years, respectively.